471 related articles for article (PubMed ID: 17973781)
1. HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo-controlled pilot study.
Bauersachs J; Störk S; Kung M; Waller C; Fidler F; Hoyer C; Frantz S; Weidemann F; Ertl G; Angermann CE
Eur J Clin Invest; 2007 Nov; 37(11):852-9. PubMed ID: 17973781
[TBL] [Abstract][Full Text] [Related]
2. Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study.
Macin SM; Perna ER; Farías EF; Franciosi V; Cialzeta JR; Brizuela M; Medina F; Tajer C; Doval H; Badaracco R
Am Heart J; 2005 Mar; 149(3):451-7. PubMed ID: 15864233
[TBL] [Abstract][Full Text] [Related]
3. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study.
Kinlay S; Schwartz GG; Olsson AG; Rifai N; Leslie SJ; Sasiela WJ; Szarek M; Libby P; Ganz P;
Circulation; 2003 Sep; 108(13):1560-6. PubMed ID: 12975259
[TBL] [Abstract][Full Text] [Related]
4. Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level.
Bleske BE; Nicklas JM; Bard RL; Brook RD; Gurbel PA; Bliden KP; Rajagopalan S; Pitt B
J Am Coll Cardiol; 2006 Jan; 47(2):338-41. PubMed ID: 16412857
[TBL] [Abstract][Full Text] [Related]
5. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
6. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial.
Päivä H; Thelen KM; Van Coster R; Smet J; De Paepe B; Mattila KM; Laakso J; Lehtimäki T; von Bergmann K; Lütjohann D; Laaksonen R
Clin Pharmacol Ther; 2005 Jul; 78(1):60-8. PubMed ID: 16003294
[TBL] [Abstract][Full Text] [Related]
7. Long-term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: a prospective randomized controlled study.
Yamada T; Node K; Mine T; Morita T; Kioka H; Tsukamoto Y; Tamaki S; Masuda M; Okuda K; Fukunami M
Am Heart J; 2007 Jun; 153(6):1055.e1-8. PubMed ID: 17540209
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD.
Dogra G; Irish A; Chan D; Watts G
Am J Kidney Dis; 2007 Jun; 49(6):776-85. PubMed ID: 17533020
[TBL] [Abstract][Full Text] [Related]
9. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure.
Sola S; Mir MQ; Lerakis S; Tandon N; Khan BV
J Am Coll Cardiol; 2006 Jan; 47(2):332-7. PubMed ID: 16412856
[TBL] [Abstract][Full Text] [Related]
10. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
[TBL] [Abstract][Full Text] [Related]
11. Alternate-day versus daily atorvastatin in coronary artery disease: a randomized study.
Rifaie O; Zahran A; Nammas W
Anadolu Kardiyol Derg; 2012 Mar; 12(2):90-6. PubMed ID: 22281786
[TBL] [Abstract][Full Text] [Related]
12. Effect of atorvastatin (10 mg/day) on glucose metabolism in patients with the metabolic syndrome.
Huptas S; Geiss HC; Otto C; Parhofer KG
Am J Cardiol; 2006 Jul; 98(1):66-9. PubMed ID: 16784923
[TBL] [Abstract][Full Text] [Related]
13. Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial.
Diepeveen SH; Verhoeven GW; Van Der Palen J; Dikkeschei LD; Van Tits LJ; Kolsters G; Offerman JJ; Bilo HJ; Stalenhoef AF
J Intern Med; 2005 May; 257(5):438-45. PubMed ID: 15836660
[TBL] [Abstract][Full Text] [Related]
14. Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein.
Kappelle PJ; Zwang L; Huisman MV; Banga JD; Sluiter WJ; Dallinga-Thie GM; Dullaart RP
Expert Opin Ther Targets; 2009 Jul; 13(7):743-51. PubMed ID: 19505224
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
[TBL] [Abstract][Full Text] [Related]
16. The effect of atorvastatin on heart rate variability and lipoproteins in patients treated with coronary bypass surgery.
Riahi S; Schmidt EB; Amanavicius N; Karmisholt J; Jensen HS; Christoffersen RP; Niebuhr U; Christensen JH; Toft E
Int J Cardiol; 2006 Aug; 111(3):436-41. PubMed ID: 16290290
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of atorvastatin after LDL-cholesterol-based dose selection in high risk dyslipidaemic patients: results of the target dose study.
Ducobu J; Claeys M; Commers K; Van Mieghem W; Nachtergaele H; Vandenbroucke M; Deforce J
Curr Med Res Opin; 2007 Aug; 23(8):1821-7. PubMed ID: 17609019
[TBL] [Abstract][Full Text] [Related]
18. Atorvastatin enhances interleukin-10 levels and improves cardiac function in rats after acute myocardial infarction.
Stumpf C; Petzi S; Seybold K; Wasmeier G; Arnold M; Raaz D; Yilmaz A; Daniel WG; Garlichs CD
Clin Sci (Lond); 2009 Jan; 116(1):45-52. PubMed ID: 18459941
[TBL] [Abstract][Full Text] [Related]
19. Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients.
Bayés B; Granada ML; Lauzurica R; Pastor MC; Navarro M; Bonet J; Llopis MA; Romero R
Transplant Proc; 2005 Nov; 37(9):3808-12. PubMed ID: 16386546
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin.
McKenney JM; Davidson MH; Shear CL; Revkin JH
J Am Coll Cardiol; 2006 Nov; 48(9):1782-90. PubMed ID: 17084250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
